WO2025038473 - TL1A BINDING ANTIBODIES AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/038473
Publication Date
20.02.2025
International Application No.
PCT/US2024/041774
International Filing Date
09.08.2024
Title **
[English]
TL1A BINDING ANTIBODIES AND METHODS OF USE
[French]
PROTÉINES DE LIAISON À TL1A ET PROCÉDÉS D'UTILISATION
Applicants **
PARAGON THERAPEUTICS, INC.
Inventors
ZHU, Eric Franklin
SHAHEEN, Hussam Hisham
RIOS, Daniel
Priority Data
63/519,056
11.08.2023
US
63/592,535
23.10.2023
US
63/599,923
16.11.2023
US
63/604,104
29.11.2023
US
63/554,897
16.02.2024
US
63/554,916
16.02.2024
US
63/559,060
28.02.2024
US
63/559,071
28.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| * | |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5773 | |
| EPO | Filing, Examination, Granting | 32022 | |
| Japan | Filing, Examination, Granting | 3051 | |
| South Korea | Filing, Examination, Granting | 4124 | |
| USA | Filing, Examination, Granting | 21390 |
Total:
66,360
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are TL1A binding proteins (e.g., antibodies that bind TL1A) and methods of use.[French]
L'invention concerne des protéines de liaison à TL1A (par exemple, des anticorps qui se lient à TL1A) et des procédés d'utilisation.